Genprex, Inc. — fact timeline

Genprex, Inc. shareholders approved Adoption and Approval of Amendment to the Certificate of Incorporation to effect a reverse stock split at the 2026-06-18 meeting.

“Proposal 5. Adoption and Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation. The amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-five (1:5) to one-for-fifty (1:50), at any time prior to December 31, 2027, subject to the Company’s Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders, was approved by the stockholders upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 2,941,032 1,592,728 61,268 0”

Genprex, Inc. shareholders approved Approval of the Amended and Restated 2018 Equity Incentive Plan at the 2026-06-18 meeting.

“Proposal 4. Approval of the Company’ s Amended and Restated 2018 Equity Incentive Plan. The proposal to approve the Amended Equity Plan was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 675,090 337,920 32,396 3,549,622”

Genprex, Inc. shareholders approved Advisory Vote on Compensation of Named Executive Officers at the 2026-06-18 meeting.

“Proposal 3. Advisory Vote on Compensation of Named Executive Officers ( “ NEOs ” ). The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company’s NEOs as described in the Company’s Proxy Statement: Votes For Votes Against Abstention Broker Non-Votes 681,841 328,425 35,140 3,549,622”

Genprex, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 4,284,497 254,937 55,594 0”

Genprex, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1. Election of Directors. The Class III director nominees, Jose Antonio Moreno Toscano and Ryan M. Confer, were elected to serve until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified, or until each such director’s earlier resignation, removal or death. The result of the votes to elect the Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Jose Antonio Moreno Toscano 868,543 176,863 3,549,622 Ryan M. Confer 877,370 168,036 3,549,622”

Genprex, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the”

Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the”

Genprex, Inc. issued up to an aggregate of 755,560 shares of Common Stock of warrant to certain investors named therein (the "Purchasers").

“the Company agreed to issue to the Purchasers warrants (the "Private Warrants") exercisable for up to an aggregate of 755,560 shares of Common Stock (the "Private Warrant Shares")”

Genprex, Inc. issued up to an aggregate of 487,244 shares of Common Stock of warrant to certain investors named in the Purchase Agreement.

“the Company agreed to issue to the Purchasers warrants (the “Private Warrants”) exercisable for up to an aggregate of 487,244 shares of Common Stock (the “Private Warrant Shares”)”

Genprex, Inc.: Certificate of Amendment to effect a one-for-fifty reverse stock split (effective 2025-10-21).

“On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”

Genprex, Inc. received a nasdaq deficiency notice notice regarding stockholders equity.

“August 19, 2025, the Company received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless”

Genprex, Inc. received a nasdaq hearing update notice regarding minimum bid price.

“received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested”

Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).

“August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.”

Genprex, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2025, Genprex, Inc. (“Genprex” or the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity of $1,391,195 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025 was below the required minimum of $2.5 millio”

Genprex, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“June 6, 2025, Genprex, Inc. (the “Company”) received a letter (the “June 2025 Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) providing written confirmation that the Company has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The June 2025 Compliance Letter was pursuant to a previous letter received on November 19, 2024 (the “November 2024 Notice”) from the Nasd”

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nas”

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid pric”

Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..

“Catherine Vaczy, the Company’s then Executive Vice President, General Counsel and Chief Strategy Officer, notified the Company of her intention to resign.”

Ryan M. Confer changed role as President, Chief Executive Officer and Chief Financial Officer at Genprex, Inc..

“Mr. Confer’s title change to President, Chief Executive Officer and Chief Financial Officer was confirmed”

Ryan Confer was appointed as Class III director at Genprex, Inc..

“On May 8, 2024, Mr. Confer was also appointed to the Board as a Class III director to fill the vacancy caused by Mr. Varner’s passing”

Ryan Confer was appointed as President and Chief Executive Officer at Genprex, Inc..

“the Board appointed Ryan Confer, Chief Financial Officer of Genprex since 2016, to serve as President and Chief Executive Officer of Genprex (in addition to his position as Chief Financial Officer of Genprex), effective immediately”

Rodney Varner departed as President and Chief Executive Officer and Chairman at Genprex, Inc..

“Rodney Varner, the Company’s President and Chief Executive Officer and Chairman of the Company’s Board of Directors (the “Board”), passed away unexpectedly on May 7, 2024 due to complications from an ongoing illness.”

Genprex, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.8 million (effective 2024-03-19).

“On March 19, 2024, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor”

Ryan Confer changed role as Chief Financial Officer at Genprex, Inc..

“the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.”

Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..

“Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.”

Catherine Vaczy resigned as other_named_officer at Genprex, Inc..

“On January 30, 2024, Catherine Vaczy provided Genprex, Inc. (“Genprex” or the “Company”) with a notice of her intention to resign pursuant to Section 7.4 of her Executive Employment Agreement”

Genprex, Inc.: Effected a one-for-forty reverse stock split of common stock via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-02-02).

“On January 31, 2024, Genprex, Inc. (the “ Company ”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “ Certificate of Amendment ”), which will effect, at 12:01 a.m. Eastern Time on February 2, 2024, a one-for-forty (1:40) reverse stock split”

Genprex, Inc. shareholders approved Amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split at the 2023-12-14 meeting.

“On December 14, 2023, Genprex, Inc., a Delaware corporation (“we” or “our” or the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The final voting results for each of the matters submitted to a vote of stockholders at the Special Meeting, as set forth in the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on November 3, 2023, are as follows: Proposal 1. Amendment to our Amended and Restated Certificate of Incorporation . The amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued shares of common stock, at a specific ratio, ranging from one-for-ten (1:10) to one-for-fifty (1:50), at any time prior to December 31, 2025, subject to our Board of Directors' determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of our stockholder”

Genprex, Inc. terminated Equity Distribution Agreement with JMP Securities LLC (effective 2023-12-12).

“On December 12, 2023, the Company provided notice of its termination of the Equity Distribution Agreement, dated as of November 18, 2022 (the “Equity Distribution Agreement”), by and between the Company and JMP Securities LLC.”

Genprex, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $25.0 million (effective 2023-12-13).

“On December 13, 2023, Genprex, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $25.0 million (the “Shares”) through the Agent (the “Offering”).”

Genprex, Inc.: Reduced stockholder meeting quorum from majority to one-third of voting power (effective 2023-10-18).

“The Amendment reduces the quorum at all meetings of the Company’s stockholders for the transaction of business, except as otherwise required by law or by the Company’s Amended and Restated Certificate of Incorporation or Bylaws, to one-third (331⁄3%) of the voting power of the stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable, or represented by proxy.”

Genprex, Inc. engaged WithumSmith+Brown, PC as its auditor.

“On September 22, 2023, Genprex, Inc. (the “Company”), upon the approval of the Audit Committee of the Company's Board of Directors, engaged WithumSmith+Brown, PC (“Withum”) as the Company’s new independent registered public accounting firm”

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 30, 2023, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasd”

CohnReznick resigned as auditor of Genprex, Inc..

“On August 21, 2023, CohnReznick confirmed to the Company that its resignation as the Company’s independent registered accounting firm had become effective on such date”

Genprex, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.

“Pursuant to an Engagement Letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds of the Offering, (iii) $50,000 for fees and expenses of the Placement Agent’s counsel and other out of pocket expenses, (iv) a non-accountable expense allowance of $25,000 and (v) $15,950 for the clearing expenses.”

Genprex, Inc. entered into Purchase Agreement with accredited healthcare-focused institutional investors valued at approximately $6.7 million (effective 2023-07-18).

“On July 18, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with accredited healthcare-focused institutional investors (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Offering”) priced at the market under Nasdaq rules, an aggregate of (i) 7,425,744 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) exercisable for up to an aggregate of 7,425,744 shares of Common Stock.”

Genprex, Inc. entered into Exclusive License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy (effective 2023-07-14).

“On July 14, 2023, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for both Type 1 and Type 2 diabetes using a MafB promoter to drive expression of the Pdx1 and MafA transcription factors.”

CohnReznick LLP resigned as auditor of Genprex, Inc..

“(“our” or “we” or the “Company”) was notified by CohnReznick LLP (“CohnReznick”), the Company’s independent registered public accounting firm, of its decision to resign as the independent registered public accounting firm of the Company effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 due to be filed by August 14, 2023. CohnReznick stated that it is providing the notice of resignation due to resource constraints. CohnReznick will remain engaged by the Company to complete its review of the Company’s interim financial statements for the quarter ended June 30, 2023.”

Genprex, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.

“The proposal to ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 25,044,860 1,105,061 230,355 0”

Genprex, Inc. shareholders approved Election of Class III Directors at the 2023-06-27 meeting.

“The Class III director nominees, Jose Antonio Moreno Toscano and J. Rodney Varner, were elected to serve until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Jose Antonio Moreno Toscano 4,856,975 3,471,721 18,051,580 J. Rodney Varner 6,899,410 1,429,286 18,051,580”

Genprex, Inc. engaged CohnReznick as its auditor.

“On April 24, 2023, upon the approval of the Audit Committee, the Company engaged CohnReznick as the Company’s new independent registered public accounting firm”

Daszkal resigned as auditor of Genprex, Inc..

“On April 24, 2023, Daszkal affirmed to the Company that it had resigned as the Company’s independent registered accounting firm.”

Genprex, Inc. entered into Securities Purchase Agreement with accredited healthcare-focused institutional investor valued at aggregate gross proceeds approximately $4.0 million (effective 2023-02-26).

“On February 26, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited healthcare-focused institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and sell to the Purchaser 3,809,524 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and common warrants to purchase an aggregate of 3,809,524 shares of Common Stock (the “Warrants”), in a registered direct offering (the “Offering”).”

Genprex, Inc. entered into UP License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at approximately $4,000,000 (effective 2022-12-29).

“As consideration for the UP License Agreement, Genprex agreed to pay UP an initial license fee, annual maintenance fees, running single digit royalties, minimum annual royalties in a fixed cash amount, a low double digit percentage share of non-royalty sublicense income, and certain milestone payments up to an aggregate of approximately $4,000,000, as well as patent prosecution expenses incurred prior to and after the effective date of the UP License Agreement.”

Genprex, Inc. entered into UP License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at approximately $4,000,000 (effective 2022-11-22).

“On November 22, 2022, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity by gene therapy to affect diabetes.”

Genprex, Inc. entered into Equity Distribution Agreement with JMP Securities LLC valued at up to $50.0 million (effective 2022-11-18).

“On November 18, 2022, Genprex, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with JMP Securities LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million (the “Shares”) through the Placement Agent (the “Offering”).”

Michael Redman was terminated as Chief Operating Officer and Executive Vice President at Genprex, Inc..

“Effective as of October 15, 2021, Michael Redman’s employment with Genprex, Inc. (the “Company”) as Chief Operating Officer and Executive Vice President of the Company was terminated.”

Michael Redman changed role as Executive Vice President and Chief Operating Officer at Genprex, Inc..

“With these new appointments, Michael Redman, the Company’s Executive Vice President and Chief Operating Officer is no longer overseeing the Company’s clinical and manufacturing operations.”

Hemant Kumar was appointed as Chief Manufacturing and Technology Officer at Genprex, Inc..

“the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.”

Mark Berger was appointed as Chief Medical Officer at Genprex, Inc..

“the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.”